The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?

When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vladislav O. Sarzhevskiy, Vladimir Ia. Melnichenko, Irina V. Panshina, Nikita E. Mochkin, Vladimir S. Bogatyrov, Maria M. Borshevetskaya, Elena G. Smirnova, Anna E. Bannikova, Anastasia A. Samoylova, Aysel A. Mamedova, Anatolij A. Rukavitsin, Sergei S. Vasilev, Oleg Iu. Bronov
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	immunotherapy pseudoprogression ctla-4 pd-1 pd-l1 inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:087c99ed4f454995bde9965434ae6e7f
record_format	dspace
spelling	oai:doaj.org-article:087c99ed4f454995bde9965434ae6e7f2021-11-30T16:55:01ZThe phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?1815-14341815-144210.26442/18151434.2021.3.200952https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f2021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/88627/66807https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focus under the action of immunotherapy. As the antitumor effect of lymphocytes and macrophages is realized, the tumor decreases or disappears over time. Pseudoprogression occurs with varying frequency in various types of cancer. It may also matter which immune checkpoint inhibitors is used to treat a solid tumor or lymphoproliferative disease. Currently, several immune-related response-evaluation criteria have been developed, which can help diagnose the phenomenon of pseudoprogression. But, unfortunately, none of these criteria clearly distinguish pseudoprogression from true tumor progression. In the case of an erroneous judgment about the effect of treatment, immunotherapy ends, and the patient may not get a chance for long-term remission. Using two clinical examples (immunotherapy for metastatic kidney cancer and recurrent Hodgkin lymphoma), the authors discuss the pitfalls of evaluating the effectiveness of treatment with checkpoint inhibitors.Vladislav O. SarzhevskiyVladimir Ia. MelnichenkoIrina V. PanshinaNikita E. MochkinVladimir S. BogatyrovMaria M. BorshevetskayaElena G. SmirnovaAnna E. BannikovaAnastasia A. SamoylovaAysel A. MamedovaAnatolij A. RukavitsinSergei S. VasilevOleg Iu. BronovIP Habib O.N.articleimmunotherapypseudoprogressionctla-4pd-1pd-l1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 496-500 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	immunotherapy pseudoprogression ctla-4 pd-1 pd-l1 inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy pseudoprogression ctla-4 pd-1 pd-l1 inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vladislav O. Sarzhevskiy Vladimir Ia. Melnichenko Irina V. Panshina Nikita E. Mochkin Vladimir S. Bogatyrov Maria M. Borshevetskaya Elena G. Smirnova Anna E. Bannikova Anastasia A. Samoylova Aysel A. Mamedova Anatolij A. Rukavitsin Sergei S. Vasilev Oleg Iu. Bronov The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
description	When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focus under the action of immunotherapy. As the antitumor effect of lymphocytes and macrophages is realized, the tumor decreases or disappears over time. Pseudoprogression occurs with varying frequency in various types of cancer. It may also matter which immune checkpoint inhibitors is used to treat a solid tumor or lymphoproliferative disease. Currently, several immune-related response-evaluation criteria have been developed, which can help diagnose the phenomenon of pseudoprogression. But, unfortunately, none of these criteria clearly distinguish pseudoprogression from true tumor progression. In the case of an erroneous judgment about the effect of treatment, immunotherapy ends, and the patient may not get a chance for long-term remission. Using two clinical examples (immunotherapy for metastatic kidney cancer and recurrent Hodgkin lymphoma), the authors discuss the pitfalls of evaluating the effectiveness of treatment with checkpoint inhibitors.
format	article
author	Vladislav O. Sarzhevskiy Vladimir Ia. Melnichenko Irina V. Panshina Nikita E. Mochkin Vladimir S. Bogatyrov Maria M. Borshevetskaya Elena G. Smirnova Anna E. Bannikova Anastasia A. Samoylova Aysel A. Mamedova Anatolij A. Rukavitsin Sergei S. Vasilev Oleg Iu. Bronov
author_facet	Vladislav O. Sarzhevskiy Vladimir Ia. Melnichenko Irina V. Panshina Nikita E. Mochkin Vladimir S. Bogatyrov Maria M. Borshevetskaya Elena G. Smirnova Anna E. Bannikova Anastasia A. Samoylova Aysel A. Mamedova Anatolij A. Rukavitsin Sergei S. Vasilev Oleg Iu. Bronov
author_sort	Vladislav O. Sarzhevskiy
title	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
title_short	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
title_full	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
title_fullStr	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
title_full_unstemmed	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
title_sort	phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f
work_keys_str_mv	AT vladislavosarzhevskiy thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT vladimiriamelnichenko thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT irinavpanshina thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT nikitaemochkin thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT vladimirsbogatyrov thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT mariamborshevetskaya thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT elenagsmirnova thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT annaebannikova thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT anastasiaasamoylova thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT ayselamamedova thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT anatolijarukavitsin thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT sergeisvasilev thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT olegiubronov thephenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT vladislavosarzhevskiy phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT vladimiriamelnichenko phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT irinavpanshina phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT nikitaemochkin phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT vladimirsbogatyrov phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT mariamborshevetskaya phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT elenagsmirnova phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT annaebannikova phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT anastasiaasamoylova phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT ayselamamedova phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT anatolijarukavitsin phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT sergeisvasilev phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous AT olegiubronov phenomenonofpseudoprogressionincancerimmunotherapyiseverythingsounambiguous
_version_	1718406424306909184

The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?

Ejemplares similares